ClinicalTrials.gg
RecruitingNCT07198750HIPEMF-OAKUpdated Sep 30, 2025

"Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis"

An interventional study of HI-PEMF - Knee (Chronic Pain Protocol) and HI-PEMF - Quadriceps (Muscle Strengthening Protocol) in Knee Osteoarthritis, Osteoarthritis and Osteo Arthritis of the Knee, sponsored by Hospital Civil de Guadalajara. Recruiting at 1 site in Mexico. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by Hospital Civil de Guadalajara · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Osteoarthritis, Knee with a site in Mexico — 2 open to participants now, 2 under way, none of them phase 3. Osteoarthritis, Knee · Mexico.

Planned enrollment
13th of 16
64 · median 110
Started
2025
with 1 other
No phase
6 of 18
1 open now
Registered
15th of 18
by date
Lead sponsor
3 of 18
Hospital Civil de Guadalajara

Among the 18 studies in Osteoarthritis, Knee with a site in Mexico, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 with no phase, and was the 15th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

2 of the 18 studies in Osteoarthritis, Knee with a site in Mexico are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Osteoarthritis, Knee with a site in Mexico, or all of them as a file.
02

Study summary

This randomized, double-blind clinical trial aims to evaluate the effect of high-intensity pulsed electromagnetic field therapy (HI-PEMF) applied either exclusively on the knee joint or bimodally on the knee and quadriceps, in older adults with knee osteoarthritis. Both groups will also receive a structured home-based exercise program. The primary outcome is pain reduction, and secondary outcomes include functional performance.

Read the detailed description

Knee osteoarthritis (OA) is a highly prevalent and disabling condition in older adults. It often coexists with quadriceps muscle weakness, sarcopenia, and frailty, all of which contribute to pain, functional decline, and loss of independence. Pulsed electromagnetic field therapy (PEMF) has emerged as a non-invasive alternative for pain relief in OA, with growing interest in its application at both articular and muscular levels.

High-intensity pulsed electromagnetic field (HI-PEMF) therapy-also known as the super inductive system-generates magnetic fields up to 2.5 Tesla, capable of stimulating both joint structures and skeletal muscle via deep tissue electric induction. HI-PEMF has shown promising results for pain reduction, anti-inflammatory modulation, and muscle bioactivation, particularly when applied over the quadriceps.

This randomized, double-blind, parallel-assignment clinical trial aims to compare the effects of two HI-PEMF treatment modalities in older adults with moderate to severe knee OA (Kellgren-Lawrence grade II-IV):

  • Group A: HI-PEMF applied exclusively over the symptomatic knee.
  • Group 2: HI-PEMF applied both over the knee and the quadriceps (bimodal). Both groups will also perform a standardized home-based strengthening and mobility exercise program.

A total of 64 participants (32 per group) will receive 9 sessions of HI-PEMF (2 per week for 5 weeks), using the BTL-6000 Super Inductive System. Outcomes will be assessed at baseline and post-intervention. The primary outcome is change in pain intensity using the Numeric Analog Scale (NAS). Secondary outcomes include functional tests (Timed Up and Go and 5-times Sit-to-Stand), and paracetamol use. Exploratory subgroup analyses will assess associations with frailty status (FRAIL), probable sarcopenia (SARC-F), and radiological OA grade.

This study seeks to generate evidence on the potential synergistic benefits of combining articular and muscular HI-PEMF therapy in geriatric rehabilitation. It is designed for implementation in a public hospital setting in Mexico, with minimal risk and high feasibility. All procedures follow ethical guidelines and have received institutional review board approval.

03

Conditions studied

  • Knee Osteoarthritis
  • Osteoarthritis
  • Osteo Arthritis of the Knee
  • Gonarthrosis

Keywords

  • High-Intensity Pulsed Electromagnetic Fields
  • HI-PEMF
  • Super Inductive System
  • Knee Osteoarthritis
  • Gonarthrosis
  • Geriatric Rehabilitation
  • Chronic Pain
  • Functional Mobility
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age ≥ 60
  • Clinical and radiological diagnosis of knee OA grade I-IV
  • Pain ≥ 3 on Numeric Analog Scale for >6 months
  • Can walk (with/without aid)
  • Cognitive ability to follow instructions
  • Signed
  • Availability for 9 treatment sessions and home exercise Exclusion Criteria
  • Prior total knee arthroplasty (unilateral or bilateral)
  • Neurological disorders affecting motor function or cognition (e.g., Parkinson's disease, stroke, moderate to severe dementia)
  • Active inflammatory rheumatic diseases (e.g., rheumatoid arthritis, lupus)
  • Presence of pacemakers, implantable defibrillators, or metallic implants near the treatment area
  • Current use of other physical therapy modalities for pain (e.g., electrotherapy, ultrasound, TENS) outside the study protocol
  • Participation in another clinical trial within the past 3 months
  • Current use of NSAIDs or systemic/local (including intra-articular injections)
  • Open wounds or active infections at the treatment site
  • Decompensated cardiac conditions or medical to exercise
  • Vestibular disorders that affect balance and interfere with functional assessments
  • Uncorrected visual impairment interfering with gait or balance (visual acuity worse than 20/60 in the better eye, assessed by Snellen chart)

Withdrawal Criteria:

  • Participants who complete fewer than 7 out of the 9 planned intervention sessions (i.e., less than 80% adherence)
  • Occurrence of serious adverse events related to the intervention that contraindicate continuation
  • Repeated non-compliance with the home exercise program, documented in at least two consecutive weekly follow-up reports
  • Voluntary withdrawal of consent at any time during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Group A - Unimodal HI-PEMF

    Participants in Group A will receive high-intensity pulsed electromagnetic field therapy (HI-PEMF) applied exclusively to the symptomatic knee (femorotibial joint) for 10 minutes per session, twice a week over 5 weeks, completing a total of 9 sessions. The intervention will use the "Chronic Pain" protocol of the BTL-6000 Super Inductive System. A standardized home-based exercise program will be provided to all participants.

    Device: HI-PEMF - Knee (Chronic Pain Protocol) · Behavioral: Home-Based Exercise Program

  • Experimental
    Group B - Bimodal HI-PEMF

    Participants in Group B will receive high-intensity pulsed electromagnetic field therapy (HI-PEMF) applied to both the symptomatic knee (femorotibial joint) and the quadriceps muscle (rectus femoris), with 10 minutes per site, twice a week over 5 weeks, completing a total of 9 sessions. The knee application will follow the "Chronic Pain" protocol, and the quadriceps application will follow the "Muscle Strengthening" protocol, both using the BTL-6000 Super Inductive System. A standardized home-based exercise program will be provided to all participants.

    Device: HI-PEMF - Quadriceps (Muscle Strengthening Protocol) · Behavioral: Home-Based Exercise Program

Interventions

  • DeviceHI-PEMF - Knee (Chronic Pain Protocol)

    High-intensity pulsed electromagnetic field (HI-PEMF) therapy applied to the symptomatic knee using the "Chronic Pain" protocol of the BTL-6000 Super Inductive System, 10-minute duration per session, applied twice per week over 5 weeks (total of 9 sessions). The applicator is positioned 2-3 cm above the patella, without skin contact, with the patient seated or in supine position.

  • DeviceHI-PEMF - Quadriceps (Muscle Strengthening Protocol)

    HI-PEMF therapy will be applied to both the symptomatic knee and the quadriceps muscle (rectus femoris). The knee application will follow the same procedure as in Group A, using the "Chronic Pain" protocol of the BTL-6000 Super Inductive System. In addition, the quadriceps will be treated using the "Muscle Strengthening" protocol. Each site will receive 10 minutes of therapy per session, twice per week over 5 weeks (total of 9 sessions). The applicator for the quadriceps will be positioned perpendicular to the muscle belly, without skin contact, with the patient lying supine and a cushion under the knee for slight flexion.

  • BehavioralHome-Based Exercise Program

    Standardized home-based exercise program prescribed to both groups. It includes five exercises: isometric quadriceps contractions, straight leg raises, seated knee extensions, sit-to-stand from chair, and stationary marching. Participants are instructed to perform the exercises three times per week during the 5-week intervention. Printed instructions and a video guide are provided. Adherence is reinforced via weekly follow-up.

06

What researchers measure

Primary outcomes

  1. Change in pain intensity measured by the Numeric Analog Scale (NAS)

    Pain intensity will be assessed using the 11-point Numeric Analog Scale (0 = no pain, 10 = worst possible pain), reported by the patient at rest and related to the most symptomatic knee. The primary endpoint is the change in NAS score from baseline to end of the 5-week intervention and at 2-month follow-up (approximately week 13). This will allow evaluation of both immediate and sustained effects of the intervention.

    Time frame: Baseline, end of intervention (week 5), and 2-month follow-up

Secondary outcomes

  1. Change in functional mobility measured by the Timed Up and Go (TUG) test

    Functional mobility will be assessed using the Timed Up and Go (TUG) test. Participants are instructed to stand up from a chair, walk 3 meters, turn around, return, and sit down. The total time (in seconds) will be recorded using a stopwatch. The outcome measure is the change in time from baseline to the end of the 5-week intervention and at 2-month follow-up. This assesses both short-term and sustained improvements in functional mobility.

    Time frame: Baseline, end of intervention (week 5), and 2-month follow-up

  2. Change in lower-limb functional strength measured by the 5-times Sit-to-Stand (5STS) test

    Lower-limb functional strength will be assessed using the 5-times Sit-to-Stand (5STS) test. Participants will be instructed to rise from a standard chair and sit back down five times as quickly as possible without using their arms. The total time (in seconds) to complete the task will be recorded using a stopwatch. The outcome measure is the change in time from baseline to the end of the 5-week intervention and at 2-month follow-up. This evaluates improvements in functional lower-limb strength and endurance over time.

    Time frame: Baseline, end of intervention (week 5), and 2-month follow-up

07

Study locations

1 of 1 sites recruiting
  • Hospital Civil de Guadalajara "Fray Antonio Alcalde"
    Guadalajara, Jalisco 44280, Mexico
    Recruiting
    • Ana L Villagrana Rodríguez, MD · Contactalvillagrana@hcg.gob.mx · +523324261190
    • Ileana Díaz Solís, MD · Contactinforehabilitacion.ids@gmail.com · +523328184251
    • Ana L Villagrana Rodríguez, MD · Principal investigator
    • Armando T Ávila García, MD, MSc · Sub investigator
    • Ileana Díaz Solís, MD · Sub investigator
    • Sara L Sáenz Guzmán, MD · Sub investigator
    • Samuel J Gaspar Rodríguez, MD · Sub investigator
    • Diana H Araiza Quintana, MD · Sub investigator
08

References and documents

Publications

  • Iannitti T, Fistetto G, Esposito A, Rottigni V, Palmieri B. Pulsed electromagnetic field therapy for management of osteoarthritis-related pain, stiffness and physical function: clinical experience in the elderly. Clin Interv Aging. 2013;8:1289-93. doi: 10.2147/CIA.S35926. Epub 2013 Sep 26. PubMed 24106421 ↗
  • Ong MT, Man GC, Lau LC, He X, Qiu J, Wang Q, Chow MC, Choi BC, Yu M, Yung PS. Effect of pulsed electromagnetic field as an intervention for patients with quadriceps weakness after anterior cruciate ligament reconstruction: a double-blinded, randomized-controlled trial. Trials. 2022 Sep 12;23(1):771. doi: 10.1186/s13063-022-06674-2. PubMed 36096886 ↗
  • Bagnato GL, Miceli G, Marino N, Sciortino D, Bagnato GF. Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo-controlled, randomized clinical trial. Rheumatology (Oxford). 2016 Apr;55(4):755-62. doi: 10.1093/rheumatology/kev426. Epub 2015 Dec 24. PubMed 26705327 ↗

Individual participant data

Plan to share: No — The individual participant data (IPD) will not be shared because the study is conducted within a public hospital setting without external funding, and there is no current plan or infrastructure to support secondary data sharing. Data will be used exclusively for the primary objectives outlined in the approved protocol.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Feb 2026, 4 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 4 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Sep 30, 2025
StartActual
Sep 15, 2025
Primary completionEst.
Feb 5, 2026
CompletionEst.
Apr 15, 2026
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07198750
Lead sponsor
Hospital Civil de Guadalajara
Responsible party
Ana Lilia Villagrana Rodríguez (Physician Specialist, Department of Physical and Rehabilitation Medicine, Hospital Civil de Guadalajara) — Principal investigator
First posted
Sep 30, 2025
Start date
Sep 15, 2025
Primary completion
Feb 5, 2026 (estimated)
Completion
Apr 15, 2026 (estimated)
Last update
Sep 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion